Endoxifen: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
== Endoxifen == | |||
[[File:Endoxifen.svg|thumb|right|Chemical structure of Endoxifen]] | |||
'''Endoxifen''' is an active metabolite of the selective estrogen receptor modulator (SERM) [[tamoxifen]]. It is primarily responsible for the therapeutic effects of tamoxifen in the treatment of [[breast cancer]]. Endoxifen is produced in the body through the metabolism of tamoxifen by the [[cytochrome P450]] enzyme system, particularly by the enzyme [[CYP2D6]]. | |||
Endoxifen is | |||
== | == Mechanism of Action == | ||
== | Endoxifen functions by binding to [[estrogen receptors]] in breast tissue, thereby inhibiting the proliferative actions of estrogen on breast cancer cells. This action is crucial in the treatment of estrogen receptor-positive (ER+) breast cancer, where estrogen promotes the growth of cancer cells. | ||
== Pharmacokinetics == | |||
The pharmacokinetics of endoxifen are influenced by genetic variations in the [[CYP2D6]] enzyme, which can affect the conversion rate of tamoxifen to endoxifen. Patients with certain genetic polymorphisms may have reduced levels of endoxifen, potentially impacting the efficacy of tamoxifen therapy. | |||
== Clinical Use == | |||
Endoxifen is not administered directly as a drug; rather, it is the active form of tamoxifen that exerts the therapeutic effects. Tamoxifen is widely used in the treatment of ER+ breast cancer in both premenopausal and postmenopausal women. The effectiveness of tamoxifen is largely attributed to the presence of endoxifen in the bloodstream. | |||
== Research and Development == | |||
Research is ongoing to develop endoxifen as a standalone therapeutic agent. This approach could potentially bypass the variability in tamoxifen metabolism and provide a more consistent therapeutic effect. Clinical trials are investigating the safety and efficacy of endoxifen in various settings, including its use in patients who are poor metabolizers of tamoxifen. | |||
== Related Pages == | |||
* [[Tamoxifen]] | * [[Tamoxifen]] | ||
* [[Estrogen receptor]] | * [[Estrogen receptor]] | ||
* [[Breast cancer]] | * [[Breast cancer]] | ||
* [[Cytochrome P450 | * [[Cytochrome P450]] | ||
* [[CYP2D6]] | |||
[[ | |||
[[Category:Selective estrogen receptor modulators]] | |||
[[Category:Breast cancer treatments]] | |||
Latest revision as of 04:01, 13 February 2025
Endoxifen[edit]
Endoxifen is an active metabolite of the selective estrogen receptor modulator (SERM) tamoxifen. It is primarily responsible for the therapeutic effects of tamoxifen in the treatment of breast cancer. Endoxifen is produced in the body through the metabolism of tamoxifen by the cytochrome P450 enzyme system, particularly by the enzyme CYP2D6.
Mechanism of Action[edit]
Endoxifen functions by binding to estrogen receptors in breast tissue, thereby inhibiting the proliferative actions of estrogen on breast cancer cells. This action is crucial in the treatment of estrogen receptor-positive (ER+) breast cancer, where estrogen promotes the growth of cancer cells.
Pharmacokinetics[edit]
The pharmacokinetics of endoxifen are influenced by genetic variations in the CYP2D6 enzyme, which can affect the conversion rate of tamoxifen to endoxifen. Patients with certain genetic polymorphisms may have reduced levels of endoxifen, potentially impacting the efficacy of tamoxifen therapy.
Clinical Use[edit]
Endoxifen is not administered directly as a drug; rather, it is the active form of tamoxifen that exerts the therapeutic effects. Tamoxifen is widely used in the treatment of ER+ breast cancer in both premenopausal and postmenopausal women. The effectiveness of tamoxifen is largely attributed to the presence of endoxifen in the bloodstream.
Research and Development[edit]
Research is ongoing to develop endoxifen as a standalone therapeutic agent. This approach could potentially bypass the variability in tamoxifen metabolism and provide a more consistent therapeutic effect. Clinical trials are investigating the safety and efficacy of endoxifen in various settings, including its use in patients who are poor metabolizers of tamoxifen.
